ClinicalTrials.gg
CompletedNCT00532948Updated Dec 7, 2016Results posted

A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas

A Phase 1 interventional study of capecitabine [Xeloda] in Glioma, sponsored by Hoffmann-La Roche. Completed at 9 sites in United States. Open to participants aged 3 Years to 21 Years. Per ClinicalTrials.gov, last updated 2016-12-07.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
3 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 851 studies in Glioma with a site in United States — 142 open to participants now, 229 under way, 6 of them phase 3. Glioma · United States.

Enrollment
407th of 737
24 · median 30
Started
2007
with 24 others
Phase 1
338 of 851
63 open now
Registered
166th of 851
by date

Among the 851 studies in Glioma with a site in United States, this one is the 407th largest by enrollment of the 737 interventional ones that give a count, is one of 25 that started in 2007, is one of 338 in phase 1, and was the 166th registered.

Glioma

1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.

Browse Glioma studies →

Open to participants now

142 of the 851 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:

137 more — sign in →

All 142 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.

This study: 3 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Glioma with a site in United States, or all of them as a file.
02

Study summary

This single arm study will assess the maximum tolerated dose, and dose-limiting toxicities, of Xeloda administered concurrently with radiation therapy, in children with newly diagnosed diffuse intrinsic brain stem gliomas and high grade gliomas. Xeloda will be administered twice daily, at a starting dose of 500mg/m2 bid, beginning within 24 hours of the start of radiation therapy. Subsequent dose escalations will be in increments of 30%, using a standard dose escalation schema. Post-radiation therapy with Xeloda will continue after a 2 week break. The anticipated time on study treatment is 3-12 months, and the target sample size will not exceed 30 evaluable patients.

03

Conditions studied

  • Glioma

Browse trials for

04

Who can participate

Ages eligible
3 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients >=3 and \<=21 years of age;
  • newly diagnosed non-disseminated brainstem glioma or non-disseminated high grade glioma;
  • (if >16 years) or Lansky (if \< 16 years) Performance Scale of >=50%;
  • adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • previous chemotherapy, radiation therapy, immunotherapy or bone marrow transplant;
  • uncontrolled infection;
  • known DPD deficiency.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    1

    Drug: capecitabine [Xeloda]

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of Capecitabine.

    The MTD was the dose level at which six evaluable patients had been treated and at most one patient experienced a dose limiting toxicity (DLT) and the next highest dose level was too toxic. Dose escalation occurred if 0 out of 3 or at most 1 out of 6 patients experienced DLT while being treated at a dose level; otherwise the dose was declared unsafe and thus above the MTD.

    Time frame: Upto 11 weeks.

  2. Dose Limiting Toxicities (DLTs)

    DLT was defined as any of the following events occurring during the 11 week dose-finding period: any event that leads to interruption of planned radiation for 5 consecutive days or 10 days total; Grade 4 neutropenia or thrombocytopenia; Grade 3 thrombocytopenia that required a platelet transfusion on 2 or more occasions; any Grade 3 or 4 non-hematologic toxicity (with the exception of grade 3 nausea or vomiting of less than 5 days duration, Grade 3 transaminases that returned to baseline value within 7 days of study drug interruption and that did not recur upon re-challenge with study drug, and/or Grade 3 fever or infection of \<5 days duration); Grade 2 non-hematologic toxicities that persisted for \>7 days and required treatment interruption, or any other capecitabine-related adverse events that required need for dose reduction or permanent cessation of therapy, interruption of study drug for \>7 days or recurred on re-challenge with capecitabine rapidly disintegrating tablets (RDTs).

    Time frame: Upto 11 weeks

  3. Number of Participants With Adverse Events (AE)

    An AE is an unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Toxicity was monitored and graded according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Adverse events that were not included in the CTCAEv3.0 were reported and graded under the other AE within the appropriate category.

    Time frame: Up to 06 years

  4. Number of Participants With Baseline Shift From Normal to Low or High in Hematology Parameters

    For hematology, the parameters assessed were: Hemoglobin, hematocrit, platelet count, RBC, WBC, lymphocytes, monocytes,granulocytes (blasts), neutrophils(segs, bands),eosinophils and basophils.

    Time frame: Up to 06 years

  5. Number of Participants With Baseline Shift From Normal to Low or High in Blood Chemistry Parameters

    For blood chemistry, the parameters assessed were: Sodium, potassium, calcium, magnesium, chloride, bicarbonate, total protein, albumin, alkaline phosphatase, alanine transaminase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), Lactate dehydrogenase (LDH), total bilirubin, direct bilirubin, indirect bilirubin, creatinine (serum creatinine or creatinine clearance), glucose.

    Time frame: Up to 06 years

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Capecitabine and Its Metabolites (5'-Deoxy-5-Fluorocytidine [5'-DFCR], 5'-Deoxy-5-Fluorouridine [5'-DFUR], 5-Fluorouracil [5-FU] and Alpha-fluoro-beta-alanine [FBAL])

    The maximum observed plasma concentration of capecitabine and its metabolites. Participants who consented to participating in the PK studies were randomized to either sampling series A or Series B. The collection time points included 2 different series, Series A (Baseline \[pre-dose\], 10 mins, 30 mins, 1, 2.5, 6, 8 and 10 hours after dosing) and Series B (Baseline \[pre-dose\], 15 minutes, 45 minutes, 1.5, 4, 8 and 10 hours after dosing).

    Time frame: Day 1 and Day 14

  2. Time to Maximum Plasma Concentration (Tmax) of Capecitabine and Its Metabolites (5'-DFCR, 5'-DFUR, 5-FU and FBAL)

    Tmax is the corresponding time at which Cmax occurs of capecitabine and its metabolites.Participants who consented to participating in the PK studies were randomized to either sampling series A or Series B. The collection time points included 2 different series, Series A (Baseline \[pre-dose\], 10 mins, 30 mins, 1, 2.5, 6, 8 and 10 hours after dosing) and Series B (Baseline \[pre-dose\], 15 minutes, 45 minutes, 1.5, 4, 8 and 10 hours after dosing).

    Time frame: Day 1 and Day 14

  3. The Area Under the Plasma Concentration-time Curve From Time of Dosing to the Last Measurable Concentration (AUClast) of Capecitabine and Its Metabolites (5'-DFCR, 5'-DFUR, 5-FU and FBAL)

    AUC last concentration of capecitabine and its metabolites. Participants who consented to participating in the PK studies were randomized to either sampling series A or Series B. The collection time points included 2 different series, Series A (Baseline \[pre-dose\], 10 mins, 30 mins, 1, 2.5, 6, 8 and 10 hours after dosing) and Series B (Baseline \[pre-dose\], 15 minutes, 45 minutes, 1.5, 4, 8 and 10 hours after dosing).

    Time frame: Day 1 and Day 14

  4. Anti Tumor Activity

    Tumor response refers to the best response prior to failure (disease progression, death or second malignancy).

    Time frame: Up to 6 years

07

Results

Posted Mar 15, 2016

Participant flow

All participants in the study were enrolled at Pediatric Brain Tumor Consortium (PBTC) institutions in the United States of America (USA), from 24 May 2007 through 27 October 2009.

Participant flow — Overall Study
MilestoneCapecitabine 500 mg/m^2Capecitabine 650 mg/m^2Capecitabine 850 mg/m^2
Started4146
Completed092
Not completed454
Withdrew: Protocol violation100
Withdrew: Death334
Withdrew: Violation of selection criteria at entry010
Withdrew: Failure to return010

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) of Capecitabine.

The MTD was the dose level at which six evaluable patients had been treated and at most one patient experienced a dose limiting toxicity (DLT) and the next highest dose level was too toxic. Dose escalation occurred if 0 out of 3 or at most 1 out of 6 patients experienced DLT while being treated at a dose level; otherwise the dose was declared unsafe and thus above the MTD.

Time frame:
Upto 11 weeks.
Reported as:
Number · milligrams
Maximum Tolerated Dose (MTD) of Capecitabine.
milligramsCapecitabine (Overall)
Maximum Tolerated Dose (MTD) of Capecitabine.650
PrimaryDose Limiting Toxicities (DLTs)

DLT was defined as any of the following events occurring during the 11 week dose-finding period: any event that leads to interruption of planned radiation for 5 consecutive days or 10 days total; Grade 4 neutropenia or thrombocytopenia; Grade 3 thrombocytopenia that required a platelet transfusion on 2 or more occasions; any Grade 3 or 4 non-hematologic toxicity (with the exception of grade 3 nausea or vomiting of less than 5 days duration, Grade 3 transaminases that returned to baseline value within 7 days of study drug interruption and that did not recur upon re-challenge with study drug, and/or Grade 3 fever or infection of \<5 days duration); Grade 2 non-hematologic toxicities that persisted for \>7 days and required treatment interruption, or any other capecitabine-related adverse events that required need for dose reduction or permanent cessation of therapy, interruption of study drug for \>7 days or recurred on re-challenge with capecitabine rapidly disintegrating tablets (RDTs).

Time frame:
Upto 11 weeks
Reported as:
Number · Participants
Dose Limiting Toxicities (DLTs)
ParticipantsCapecitabine 500 mg/m^2Capecitabine 650 mg/m^2Capecitabine 850 mg/m^2
Dose Limiting Toxicities (DLTs)033
PrimaryNumber of Participants With Adverse Events (AE)

An AE is an unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Toxicity was monitored and graded according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Adverse events that were not included in the CTCAEv3.0 were reported and graded under the other AE within the appropriate category.

Time frame:
Up to 06 years
Reported as:
Number · Participants
Number of Participants With Adverse Events (AE)
ParticipantsCapecitabine 500 mg/m^2Capecitabine 650 mg/m^2Capecitabine 850 mg/m^2
Number of Participants With Adverse Events (AE)3126
PrimaryNumber of Participants With Baseline Shift From Normal to Low or High in Hematology Parameters

For hematology, the parameters assessed were: Hemoglobin, hematocrit, platelet count, RBC, WBC, lymphocytes, monocytes,granulocytes (blasts), neutrophils(segs, bands),eosinophils and basophils.

Time frame:
Up to 06 years
Reported as:
Number · Participants
Number of Participants With Baseline Shift From Normal to Low or High in Hematology Parameters
ParticipantsCapecitabine 500 mg/m^2Capecitabine 650 mg/m^2Capecitabine 850 mg/m^2
Haematocrit, normal to low, n=3,1,5214
Haematocrit, normal to high, n=3,1,5000
Hemoglobin, normal to low, n=4,2,6002
Hemoglobin, normal to high, n=4,2,6000
White blood cell, normal to low, n=3,1,5000
White blood cell, normal to high, n=3,1,5111
Platelets, normal to low, n=4,2,6010
Platelets, normal to high, n=4,2,6001
Red blood cells, normal to low, n=3,1,3201
Red blood cells, normal to high, n=3,1,3010
Neutrophils (segmented), normal to low , n=3,0,5000
Neutrophils (segmented), normal to high, n=3,0,5000
Basophils (relative), normal to low, n=0,1,2000
Basophils (relative), normal to high, n=0,1,2012
Lymphocytes (relative), normal to low, n=3,1,5000
Lymphocytes (relative), normal to high, n=3,1,5000
Monocytes (relative), normal to low, n=3,1,4000
Monocytes (relative), normal to high, n=3,1,4103
Eosinophils (relative), normal to low, n=1,1,3010
Eosinophils (relative), normal to high, n=1,1,3000
PrimaryNumber of Participants With Baseline Shift From Normal to Low or High in Blood Chemistry Parameters

For blood chemistry, the parameters assessed were: Sodium, potassium, calcium, magnesium, chloride, bicarbonate, total protein, albumin, alkaline phosphatase, alanine transaminase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), Lactate dehydrogenase (LDH), total bilirubin, direct bilirubin, indirect bilirubin, creatinine (serum creatinine or creatinine clearance), glucose.

Time frame:
Up to 06 years
Reported as:
Number · Participants
Number of Participants With Baseline Shift From Normal to Low or High in Blood Chemistry Parameters
ParticipantsCapecitabine 500 mg/m^2Capecitabine 650 mg/m^2Capecitabine 850 mg/m^2
Lactic dehydrogenase, normal to low, n=0,0,0000
Lactic dehydrogenase, normal to high, n=0,0,0000
Indirect bilirubin, normal to low, n=1,1,1000
Indirect bilirubin, normal to high, n=1,1,1010
BUN, normal to low, n=3,1,5002
BUN, normal to high, n=3,1,5011
Alkaline phosphatase, normal to low, n=1,1,4001
Alkaline phosphatase, normal to high, n=1,1,4000
Direct blirubin, normal to low, n=2,1,1000
Direct bilirubin, normal to high, n=2,1,1000
Total bilirubin, normal to low, n=4,2,6000
Total bilirubin, normal to high, n=4,2,6000
Fasting glucose, normal to low, n=1,0,4000
Fasting glucose, normal to high, n=1,0,4000
Protein, normal to low, n=1,0,2101
Protein, normal to high, n=1,0,2000
Serum albumin, normal to low, n=3,1,5201
Serum albumin, normal to high, n=3,1,5000
Serum creatinine, normal to low, n=4,2,6000
Serum creatinine, normal to high, n=4,2,6002
ASAT (SGOT), normal to low, n=1,0,4000
ASAT (SGOT), normal to high, n=1,0,4002
ALAT (SGPT), normal to low, n=4,2,6000
ALAT (SGPT), normal to high, n=4,2,6224
Calcium, normal to low, n=3, 1,5110
Calcium, normal to high, n=3,1,5001
Phosphate, normal to low, n=3,1,5101
Phosphate, normal to high, n=3,1,5001
Potassium, normal to low, n=3, 1,5200
Potassium, normal to high, n=3,1,5010
Sodium, normal to low, n=3,1,5113
Sodium, normal to high, n=3,1,5000
Magnesium, normal to low, n=3,1,5000
Magnesium, normal to high, n=3,1,5110
Chloride, normal to low, n=3,1,5001
Chloride, normal to high, n=3,1,5011
Bicarbonate, normal to low, n=3,0,5000
Bicarbonate, normal to high, n=3,0,5003
SecondaryMaximum Observed Plasma Concentration (Cmax) of Capecitabine and Its Metabolites (5'-Deoxy-5-Fluorocytidine [5'-DFCR], 5'-Deoxy-5-Fluorouridine [5'-DFUR], 5-Fluorouracil [5-FU] and Alpha-fluoro-beta-alanine [FBAL])

The maximum observed plasma concentration of capecitabine and its metabolites. Participants who consented to participating in the PK studies were randomized to either sampling series A or Series B. The collection time points included 2 different series, Series A (Baseline \[pre-dose\], 10 mins, 30 mins, 1, 2.5, 6, 8 and 10 hours after dosing) and Series B (Baseline \[pre-dose\], 15 minutes, 45 minutes, 1.5, 4, 8 and 10 hours after dosing).

Time frame:
Day 1 and Day 14
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Capecitabine and Its Metabolites (5'-Deoxy-5-Fluorocytidine [5'-DFCR], 5'-Deoxy-5-Fluorouridine [5'-DFUR], 5-Fluorouracil [5-FU] and Alpha-fluoro-beta-alanine [FBAL])
ng/mLCapecitabine 500 mg/m^2Capecitabine 650 mg/m^2Capecitabine 850 mg/m^2
Capecitabine, Day 1, n= 2, 4, 31440 ± 7503080 ± 13401890 ± 1420
Capecitabine, Day 14, n=2,2,22100 ± 17705440 ± 32703710 ± 156
5'-DFCR, Day 1, n=2,4,32050 ± 8132190 ± 6262180 ± 1690
5'-DFCR, Day 14, n=2,2,22980 ± 20203500 ± 14703200 ± 233
5'-DFUR, Day 1, n=2,4,31910 ± 8342640 ± 17003770 ± 3300
5'-DFUR, Day 14, n=2,2,23300 ± 28003120 ± 4455020 ± 1220
FBAL, Day 1, n=2,4,31350 ± 1341740 ± 3652050 ± 1640
FBAL, Day 14, n=2,2,21770 ± 4102430 ± 84.92140 ± 304
SecondaryTime to Maximum Plasma Concentration (Tmax) of Capecitabine and Its Metabolites (5'-DFCR, 5'-DFUR, 5-FU and FBAL)

Tmax is the corresponding time at which Cmax occurs of capecitabine and its metabolites.Participants who consented to participating in the PK studies were randomized to either sampling series A or Series B. The collection time points included 2 different series, Series A (Baseline \[pre-dose\], 10 mins, 30 mins, 1, 2.5, 6, 8 and 10 hours after dosing) and Series B (Baseline \[pre-dose\], 15 minutes, 45 minutes, 1.5, 4, 8 and 10 hours after dosing).

Time frame:
Day 1 and Day 14
Reported as:
Median · Hour
Time to Maximum Plasma Concentration (Tmax) of Capecitabine and Its Metabolites (5'-DFCR, 5'-DFUR, 5-FU and FBAL)
HourCapecitabine 500 mg/m^2Capecitabine 650 mg/m^2Capecitabine 850 mg/m^2
Capecitabine, Day 1, n= 2, 4, 30.58 (0.17 to 1)0.63 (0.25 to 1)0.85 (0.83 to 10)
Capecitabine, Day 14, n=2,2,21.33 (0.17 to 2.48)0.82 (0.8 to 0.83)0.61 (0.5 to 0.72)
5'-DFCR, Day 1, n=2,4,31.0 (1.0 to 1.0)0.75 (0.50 to 2.50)1.55 (0.85 to 10)
5'-DFCR, Day 14, n=2,2,21.49 (0.5 to 2.48)1.18 (0.5 to 1.53)0.61 (0.5 to 1.53)
5'-DFUR, Day 1, n=2,4,31 (1 to 1)0.9 (0.7 to 2.5)1.5 (0.75 to 10)
5'-DFUR, Day 14, n=2,2,21.5 (0.5 to 2.5)0.82 (0.8 to 0.83)0.61 (0.5 to 0.72)
5-FU, Day 1, n=2,4,31 (1 to 1)0.75 (0.5 to 2.5)1.5 (0.75 to 10)
5-FU, Day 14, n=2,2,21.5 (0.5 to 2.5)0.83 (0.8 to 0.83)1 (0.5 to 1.5)
FBAL, Day 1, n=2,4,32.53 (2.5 to 2.53)1.5 (1.5 to 2.5)1.55 (1.42 to 10)
FBAL, Day 14, n=2,2,21.74 (1 to 2.5)2.2 (1.5 to 2.8)2.03 (1.57 to 2.5)
SecondaryThe Area Under the Plasma Concentration-time Curve From Time of Dosing to the Last Measurable Concentration (AUClast) of Capecitabine and Its Metabolites (5'-DFCR, 5'-DFUR, 5-FU and FBAL)

AUC last concentration of capecitabine and its metabolites. Participants who consented to participating in the PK studies were randomized to either sampling series A or Series B. The collection time points included 2 different series, Series A (Baseline \[pre-dose\], 10 mins, 30 mins, 1, 2.5, 6, 8 and 10 hours after dosing) and Series B (Baseline \[pre-dose\], 15 minutes, 45 minutes, 1.5, 4, 8 and 10 hours after dosing).

Time frame:
Day 1 and Day 14
Reported as:
Mean · h*ng/mL
The Area Under the Plasma Concentration-time Curve From Time of Dosing to the Last Measurable Concentration (AUClast) of Capecitabine and Its Metabolites (5'-DFCR, 5'-DFUR, 5-FU and FBAL)
h*ng/mLCapecitabine 500 mg/m^2Capecitabine 650 mg/m^2Capecitabine 850 mg/m^2
Capecitabine, Day 1, n= 2, 4, 33370 ± 6075160 ± 37003470 ± 1170
Capecitabine, Day 14, n=2,2,22890 ± 6559660 ± 33405670 ± 971
5'-DFCR, Day 1, n=2,4,35250 ± 7555140 ± 34404180 ± 2380
5'-DFCR, Day 14, n=2,2,24300 ± 27.29250 ± 14006520 ± 452
5'-DFUR, Day 1, n=2,4,34790 ± 7844300 ± 16006650 ± 3740
5'-DFUR, Day 14, n=2,2,24240 ± 9298010 ± 189010500 ± 445
5-FU Day 1, n=2,4,381.6 ± 29.7114 ± 40.9271 ± 205
5-FU Day 14, n=2,2,2181 ± 84.7253 ± 16.3499 ± 78.8
FBAL, Day 1, n=2,4,35990 ± 9518110 ± 16407010 ± 4490
FBAL, Day 14, n=2,2,25720 ± 69010700 ± 57410400 ± 1760
SecondaryAnti Tumor Activity

Tumor response refers to the best response prior to failure (disease progression, death or second malignancy).

Time frame:
Up to 6 years

No measurements were reported for this outcome.

Adverse events

Collected over Up to 6 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine 500 mg/m^2—2/4 (50%)3/4 (75%)
Capecitabine 650 mg/m^2—1/12 (8.3%)12/12 (100%)
Capecitabine 850 mg/m^2—3/6 (50%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventCapecitabine 500 mg/m^2Capecitabine 650 mg/m^2Capecitabine 850 mg/m^2
HydrocephalusNervous system disorders1/40/120/6
LeukopeniaBlood and lymphatic system disorders1/40/120/6
ConvulsionNervous system disorders0/40/121/6
Skin ExfoliationSkin and subcutaneous tissue disorders0/40/121/6
Abdominal InfectionInfections and infestations0/40/121/6
Blood Creatinine IncreasedInvestigations0/40/121/6
Dermatitis ExfoliativeSkin and subcutaneous tissue disorders0/41/120/6
PainGeneral disorders0/41/120/6
HyperglycaemiaMetabolism and nutrition disorders0/41/120/6
Most frequent other events
Showing 10 of 70
Most frequent other events
EventCapecitabine 500 mg/m^2Capecitabine 650 mg/m^2Capecitabine 850 mg/m^2
LymphopeniaBlood and lymphatic system disorders3/410/123/6
LeukopeniaBlood and lymphatic system disorders3/410/122/6
Alanine aminotransferase increasedInvestigations1/49/123/6
VomitingGastrointestinal disorders2/49/122/6
Abdominal painGastrointestinal disorders0/44/124/6
NauseaGastrointestinal disorders1/42/124/6
Skin exfoliationSkin and subcutaneous tissue disorders1/48/124/6
Neutrophil countInvestigations2/44/121/6
Platelet count decreasedInvestigations2/45/120/6
HypokalaemiaMetabolism and nutrition disorders2/43/122/6

Baseline characteristics

Intent to treat population defined as all participants enrolled.

Age, Continuous
Age, Continuous(years)Capecitabine 500 mg/m^2Capecitabine 650 mg/m^2Capecitabine 850 mg/m^2Total
Mean7.5 ± 1.738.4 ± 2.6513 ± 3.419.37 ± 3.39
Gender
Gender(Participants)Capecitabine 500 mg/m^2Capecitabine 650 mg/m^2Capecitabine 850 mg/m^2Total
Female112215
Male3249
08

Study locations

9 sites
  • San Francisco, California 94143-0780, United States
  • Washington, District of Columbia 20010, United States
  • Chicago, Illinois 60614, United States
  • Boston, Massachusetts 02115-6084, United States
  • Durham, North Carolina 27710, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Pittsburgh, Pennsylvania 15261, United States
  • Houston, Texas 77030, United States
  • Seattle, Washington 98105, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2007
First posted
Sep 21, 2007
Start
May 2007
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Mar 15, 2016
Last update
Dec 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00532948
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 21, 2007
Start date
May 2007
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Mar 15, 2016
Last update
Dec 7, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion